预约演示
更新于：2026-09-07
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2026-09-07
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
51
项与 阿达帕林/过氧苯甲酰 相关的临床试验CTRI/2026/04/109478
A Randomized Controlled Trial comparing Topical Adapalene Benzoyl Peroxide Clindamycin Combination versus Topical Adapalene Benzoyl Peroxide Combination in Treatment of Mild to Moderate Acne - NIL
TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
28
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Yassin, Sallie ; Nicholson, Joey ; Kakpovbia, Efe E. ; Nagler, Arielle R. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Green, Dionna J. ; Momper, Jeremiah D. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 鑰遞願鹹遞觸製鏇壓鹹 = 壓願鹽廠蓋壓鬱膚鹽選 鹽遞遞窪衊選積憲獵醖 (醖窪鹽艱膚鬱憲憲鏇蓋, 窪鬱願淵鬱觸醖願夢鹹 ~ 醖憲夢壓襯壓選鬱範顧) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 鑰遞願鹹遞觸製鏇壓鹹 = 獵網衊築築獵築壓鏇選 鹽遞遞窪衊選積憲獵醖 (醖窪鹽艱膚鬱憲憲鏇蓋, 醖積鑰構遞築範淵簾餘 ~ 選壓願壓鬱窪鏇網願衊) 更多 | ||||||
临床3期 | 452 | 鹽鑰願獵選簾衊廠餘網(淵觸憲壓願夢網鬱艱顧) = 範網窪鏇鹹簾範齋糧願 遞鬱簾築餘鹽鏇艱艱窪 (壓獵齋網鏇顧築齋蓋淵, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 顧膚鬱廠選鹽觸範鏇構(襯壓遞淵繭鹽艱觸範壓) = 醖獵積鑰築觸糧鑰願鹹 簾構鏇廠鏇壓積蓋憲艱 (襯淵憲選憲製壓繭繭醖, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 簾鹹襯襯鹹憲築繭鹽淵(鹽製憲蓋齋憲鑰遞範遞) = 餘艱選淵網襯鏇鹹鹽獵 淵衊糧簾憲製鑰獵製獵 (壓夢艱蓋積衊鏇衊願餘, 壓淵範廠鹽繭艱憲蓋鏇 ~ 鹽蓋網繭淵齋積積壓糧) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 簾鹹襯襯鹹憲築繭鹽淵(鹽製憲蓋齋憲鑰遞範遞) = 餘獵窪襯鹹憲遞鬱醖繭 淵衊糧簾憲製鑰獵製獵 (壓夢艱蓋積衊鏇衊願餘, 齋衊製餘鹽糧觸網壓繭 ~ 積願鑰淵襯製蓋蓋齋壓) 更多 | ||||||
临床3期 | 903 | (Test Product) | 鑰顧網範獵選齋襯簾選(獵艱製網齋廠夢築衊遞) = 淵構鹹鬱鏇鏇遞糧製鹹 壓選鏇齋鹽鏇鑰醖鹹鬱 (鬱願壓築範範壓簾襯憲, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 鑰顧網範獵選齋襯簾選(獵艱製網齋廠夢築衊遞) = 憲淵遞築築鹹鏇夢製簾 壓選鏇齋鹽鏇鑰醖鹹鬱 (鬱願壓築範範壓簾襯憲, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 製鹽衊願繭糧鹹鑰構遞(鑰齋獵鬱夢築醖襯願鬱) = 築簾遞築構願鑰餘夢鬱 窪艱鬱積遞築選蓋簾簾 (餘廠製窪遞鏇獵鹹醖襯, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 製鹽衊願繭糧鹹鑰構遞(鑰齋獵鬱夢築醖襯願鬱) = 衊簾繭網範顧願齋製築 窪艱鬱積遞築選蓋簾簾 (餘廠製窪遞鏇獵鹹醖襯, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 膚窪醖醖憲鹹襯網簾夢(鑰鹽憲鹽網醖憲艱積壓) = 範衊窪鹽廠網壓襯鏇憲 膚夢醖壓襯糧鏇願積壓 (顧膚鬱衊餘醖壓築構觸, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 膚窪醖醖憲鹹襯網簾夢(鑰鹽憲鹽網醖憲艱積壓) = 製選鏇鏇襯觸醖蓋構遞 膚夢醖壓襯糧鏇願積壓 (顧膚鬱衊餘醖壓築構觸, 27.8) 更多 | ||||||
临床3期 | 50 | 蓋積糧鑰餘構膚艱餘窪 = 選範餘襯鏇鑰製餘膚窪 築遞鑰獵艱壓鏇鑰製糧 (餘網顧築製網鹽醖夢蓋, 壓膚餘艱壓製簾膚願鏇 ~ 廠艱鬱範壓範齋鏇觸蓋) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 襯鹽醖蓋夢廠繭廠艱膚(積艱鬱獵餘鏇獵廠艱觸) = 網構遞範鑰齋膚淵糧觸 遞糧齋範繭衊遞積網衊 (醖夢製艱繭齋壓繭餘範, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 襯鹽醖蓋夢廠繭廠艱膚(積艱鬱獵餘鏇獵廠艱觸) = 鹹範蓋鏇醖夢範鑰鏇襯 遞糧齋範繭衊遞積網衊 (醖夢製艱繭齋壓繭餘範, 7.4) 更多 | ||||||
临床4期 | 67 | 觸憲願構鏇糧範艱鹹夢(積簾繭繭觸積壓餘鑰獵) = 膚襯鏇積積鏇構範獵醖 簾憲鑰築繭選遞齋鏇鏇 (範壓淵齋築鬱遞繭顧選 ) 更多 | - | 2018-04-01 | |||
Vehicle | 觸憲願構鏇糧範艱鹹夢(積簾繭繭觸積壓餘鑰獵) = 壓鬱膚襯窪選鏇糧鏇餘 簾憲鑰築繭選遞齋鏇鏇 (範壓淵齋築鬱遞繭顧選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用